Primed to deliver strong, predictable growth, recurring revenue and profitability, through an unmatched patient offering and network of brands

Published on
  • Share On

• We possess a track record of strong financial performance and consistent growth that has been driven by its ramp-up of assets launched in recent years and supported by its focus on treating a higher-end patient mix and cost optimization
• For the years ended 31 December 2019, 2020, and 2021, the Group’s revenue was AED 2,420.5 million, AED 2,605.2 million and AED 3,351.0 million, respectively, representing a CAGR of 17.7 per cent
• For the years ended 31 December 2019, 2020, and 2021, the Group’s EBITDA was AED 417.9 million, AED 470.2 million and AED 779.1 million, respectively, representing a CAGR of 36.5 per cent